β‐adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study
JA Pasco, MJ Henry, KM Sanders… - Journal of bone and …, 2004 - academic.oup.com
Journal of bone and mineral research, 2004•academic.oup.com
This population‐based study documented β‐blocker use in 59/569 cases with incident
fracture and 112/775 controls. OR for fracture associated with β‐blocker use was 0.68 (95%
CI, 0.49–0.96). β‐Blockers were associated with higher BMD at the total hip (2.5%) and UD
forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. β‐Blocker use is
associated with reduced fracture risk and higher BMD. Introduction: Animal data suggests
that bone formation is under β‐adrenergic control and that β‐blockers stimulate bone …
fracture and 112/775 controls. OR for fracture associated with β‐blocker use was 0.68 (95%
CI, 0.49–0.96). β‐Blockers were associated with higher BMD at the total hip (2.5%) and UD
forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. β‐Blocker use is
associated with reduced fracture risk and higher BMD. Introduction: Animal data suggests
that bone formation is under β‐adrenergic control and that β‐blockers stimulate bone …
Abstract
This population‐based study documented β‐blocker use in 59/569 cases with incident fracture and 112/775 controls. OR for fracture associated with β‐blocker use was 0.68 (95%CI, 0.49–0.96). β‐Blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. β‐Blocker use is associated with reduced fracture risk and higher BMD.
Introduction: Animal data suggests that bone formation is under β‐adrenergic control and that β‐blockers stimulate bone formation and/or inhibit bone resorption.
Materials and Methods: We evaluated the association between β‐blocker use, bone mineral density (BMD), and fracture risk in a population‐based study in Geelong, a southeastern Australian city with a single teaching hospital and two radiological centers providing complete fracture ascertainment for the region. β‐Blocker use was documented for 569 women with radiologically confirmed incident fractures and 775 controls without incident fracture. Medication use and lifestyle factors were documented by questionnaire.
Results: Odds ratio for fracture associated with β‐blocker use was 0.68 (95% CI, 0.49–0.96) for any fracture. Adjusting for age, weight, medications, and lifestyle factors had little effect on the odds ratio. β‐Blocker use was associated with a higher BMD at the total hip (2.5%, p = 0.03) and ultradistal forearm (3.6%, p = 0.04) after adjustment for age, anthropometry, and thiazide use.
Conclusion: β‐Blockers are associated with a reduction in fracture risk and higher BMD.
Oxford University Press